2024-04-25-深交所-山河药辅_2024年一季度报告_11页_267kb

Financial Performance in 2024 Q1

The company reported a revenue decrease of 4.05% to 237.69 million yuan, with net profit increasing marginally by 0.86% to 49.82 million yuan. However, net profit after non-recurring items fell by 7.56%, and operating cash flow saw a significant decline of 712.67% to -10.23 million yuan, indicating cash flow pressures.

Key Financial Highlights

• Net assets increased by 0.04%, reaching 1.54 billion yuan, while equity attributable to shareholders grew 3.17% to 893.57 million yuan.
• Non-recurring items contributed a positive gain of 7.57 million yuan, mainly from government grants and financial asset movements.

Balance Sheet Changes

Accounts receivable rose by 69.49% due to sales growth, and prepaid items increased sharply by 121.75% from higher raw material payments. Fixed assets decreased due to asset transfers, and contract liabilities declined by 31.31% amid reduced prepayments.

Shareholder Information

Major shareholders include principal owner Yin Zhenglong (holding 26.9% or 63.06 million shares) and Fosun Pharmaceutical. Top shareholders saw stable holdings, with no significant new entrants or exits noted.

Other Notes

The company's net profit margin remained around 2.1%, but financial expenses surged due to bond interest, and tax rebates decreased, affecting liquidity. The voting rights of shareholders are unaffected by recent changes.

此总结基于季度报告核心数据，格式化为易读内容。